Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

Philip A. Rowlings, Stephanie F. Williams, Karen H. Antman, Karen K. Fields, Joseph W. Fay, Elizabeth Cecile Reed, Corey J. Pelz, John P. Klein, Kathleen A. Sobocinski, M. John Kennedy, Cesar O. Freytes, Philip L. McCarthy, Roger H. Herzig, Edward A. Stadtmauer, Hillard M. Lazarus, Andrew L. Pecora, Jacob D. Bitran, Steven N. Wolff, Robert Peter Gale, James Olen Armitage & 3 others William P. Vaughan, Gary Spitzer, Mary M. Horowitz

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Context: Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about the benefits of and appropriate patients for this therapy. Objective: To determine factors associated with disease progression or death after autotransplantation in women with metastatic breast cancer. Design: Analysis of data collected retrospectively (January 1989 to 1992) and prospectively (1992 through January 1995) for the Autologous Blood and Marrow Transplant Registry. Setting: Sixty-three hospitals in North America, Brazil, and Russia. Participants: A total of 1188 consecutive women aged 18 to 70 years receiving autotransplants for metastatic or locally recurrent breast cancer, with a median follow-up of 291/2 months. Main Outcome Measure: Time to treatment failure (disease progression, disease recurrence, or death) after autotransplantation. Results: Factors associated with significantly (P<.05) increased risk of treatment failure in a Cox multivariate analysis included age older than 45 years (relative hazard, 1.17; 95% confidence interval [Cl] 1.02-1.33). Karnofsky performance score less than 90% (1.27; 95% Cl, 1.07-1.51), absence of hormone receptors (1.31; 95% Cl, 1.151.51), prior use of adjuvant chemotherapy (1.31; 95% Cl, 1.10-1.56), initial disease-free survival interval after adjuvant treatment of no more than 18 months (1.99; 95% Cl, 1.62-2.43), metastases in the liver (1.47; 95% Cl, 1.20-1.80) or central nervous system (1.56; 95% Cl, 0.99-2.46 [approaches significance]) vs soft tissue, bone, or lung, 3 or more sites of metastatic disease (1.32; 95% Cl, 1.13-1.54), and incomplete response vs complete response to standard-dose chemotherapy (1.65; 95% Cl, 1.361.99). Receiving tamoxifen posttransplantation was associated with a reduced risk of treatment failure in women with hormone receptor-positive tumors (relative hazard, 0.60; 95% Cl, 0.47-0.87). Women with no risk factors (n = 38) had a 3-year probability of progression-free survival of 43% (95% Cl, 27%-61%) vs 4% (95% Cl, 2%8%) for women with more than 3 risk factors (n = 343). Conclusion: These data indicate that some women are unlikely to benefit from autotransplantation and should receive this treatment only after being provided with prognostic information and in the context of clinical trials attempting to improve outcome.

Original languageEnglish (US)
Pages (from-to)1335-1343
Number of pages9
JournalJournal of the American Medical Association
Volume282
Issue number14
DOIs
StatePublished - Oct 13 1999

Fingerprint

Hematopoietic Stem Cell Transplantation
Disease-Free Survival
Breast Neoplasms
Drug Therapy
Autologous Transplantation
Treatment Failure
Autografts
North America
Disease Progression
Hormones
Russia
Tamoxifen
Adjuvant Chemotherapy
Brazil
Registries
Therapeutics
Multivariate Analysis
Central Nervous System
Bone Marrow
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. / Rowlings, Philip A.; Williams, Stephanie F.; Antman, Karen H.; Fields, Karen K.; Fay, Joseph W.; Reed, Elizabeth Cecile; Pelz, Corey J.; Klein, John P.; Sobocinski, Kathleen A.; Kennedy, M. John; Freytes, Cesar O.; McCarthy, Philip L.; Herzig, Roger H.; Stadtmauer, Edward A.; Lazarus, Hillard M.; Pecora, Andrew L.; Bitran, Jacob D.; Wolff, Steven N.; Gale, Robert Peter; Armitage, James Olen; Vaughan, William P.; Spitzer, Gary; Horowitz, Mary M.

In: Journal of the American Medical Association, Vol. 282, No. 14, 13.10.1999, p. 1335-1343.

Research output: Contribution to journalArticle

Rowlings, PA, Williams, SF, Antman, KH, Fields, KK, Fay, JW, Reed, EC, Pelz, CJ, Klein, JP, Sobocinski, KA, Kennedy, MJ, Freytes, CO, McCarthy, PL, Herzig, RH, Stadtmauer, EA, Lazarus, HM, Pecora, AL, Bitran, JD, Wolff, SN, Gale, RP, Armitage, JO, Vaughan, WP, Spitzer, G & Horowitz, MM 1999, 'Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer', Journal of the American Medical Association, vol. 282, no. 14, pp. 1335-1343. https://doi.org/10.1001/jama.282.14.1335
Rowlings, Philip A. ; Williams, Stephanie F. ; Antman, Karen H. ; Fields, Karen K. ; Fay, Joseph W. ; Reed, Elizabeth Cecile ; Pelz, Corey J. ; Klein, John P. ; Sobocinski, Kathleen A. ; Kennedy, M. John ; Freytes, Cesar O. ; McCarthy, Philip L. ; Herzig, Roger H. ; Stadtmauer, Edward A. ; Lazarus, Hillard M. ; Pecora, Andrew L. ; Bitran, Jacob D. ; Wolff, Steven N. ; Gale, Robert Peter ; Armitage, James Olen ; Vaughan, William P. ; Spitzer, Gary ; Horowitz, Mary M. / Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. In: Journal of the American Medical Association. 1999 ; Vol. 282, No. 14. pp. 1335-1343.
@article{1ce8145956d548489b993a0f54a8f6c6,
title = "Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer",
abstract = "Context: Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about the benefits of and appropriate patients for this therapy. Objective: To determine factors associated with disease progression or death after autotransplantation in women with metastatic breast cancer. Design: Analysis of data collected retrospectively (January 1989 to 1992) and prospectively (1992 through January 1995) for the Autologous Blood and Marrow Transplant Registry. Setting: Sixty-three hospitals in North America, Brazil, and Russia. Participants: A total of 1188 consecutive women aged 18 to 70 years receiving autotransplants for metastatic or locally recurrent breast cancer, with a median follow-up of 291/2 months. Main Outcome Measure: Time to treatment failure (disease progression, disease recurrence, or death) after autotransplantation. Results: Factors associated with significantly (P<.05) increased risk of treatment failure in a Cox multivariate analysis included age older than 45 years (relative hazard, 1.17; 95{\%} confidence interval [Cl] 1.02-1.33). Karnofsky performance score less than 90{\%} (1.27; 95{\%} Cl, 1.07-1.51), absence of hormone receptors (1.31; 95{\%} Cl, 1.151.51), prior use of adjuvant chemotherapy (1.31; 95{\%} Cl, 1.10-1.56), initial disease-free survival interval after adjuvant treatment of no more than 18 months (1.99; 95{\%} Cl, 1.62-2.43), metastases in the liver (1.47; 95{\%} Cl, 1.20-1.80) or central nervous system (1.56; 95{\%} Cl, 0.99-2.46 [approaches significance]) vs soft tissue, bone, or lung, 3 or more sites of metastatic disease (1.32; 95{\%} Cl, 1.13-1.54), and incomplete response vs complete response to standard-dose chemotherapy (1.65; 95{\%} Cl, 1.361.99). Receiving tamoxifen posttransplantation was associated with a reduced risk of treatment failure in women with hormone receptor-positive tumors (relative hazard, 0.60; 95{\%} Cl, 0.47-0.87). Women with no risk factors (n = 38) had a 3-year probability of progression-free survival of 43{\%} (95{\%} Cl, 27{\%}-61{\%}) vs 4{\%} (95{\%} Cl, 2{\%}8{\%}) for women with more than 3 risk factors (n = 343). Conclusion: These data indicate that some women are unlikely to benefit from autotransplantation and should receive this treatment only after being provided with prognostic information and in the context of clinical trials attempting to improve outcome.",
author = "Rowlings, {Philip A.} and Williams, {Stephanie F.} and Antman, {Karen H.} and Fields, {Karen K.} and Fay, {Joseph W.} and Reed, {Elizabeth Cecile} and Pelz, {Corey J.} and Klein, {John P.} and Sobocinski, {Kathleen A.} and Kennedy, {M. John} and Freytes, {Cesar O.} and McCarthy, {Philip L.} and Herzig, {Roger H.} and Stadtmauer, {Edward A.} and Lazarus, {Hillard M.} and Pecora, {Andrew L.} and Bitran, {Jacob D.} and Wolff, {Steven N.} and Gale, {Robert Peter} and Armitage, {James Olen} and Vaughan, {William P.} and Gary Spitzer and Horowitz, {Mary M.}",
year = "1999",
month = "10",
day = "13",
doi = "10.1001/jama.282.14.1335",
language = "English (US)",
volume = "282",
pages = "1335--1343",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

AU - Rowlings, Philip A.

AU - Williams, Stephanie F.

AU - Antman, Karen H.

AU - Fields, Karen K.

AU - Fay, Joseph W.

AU - Reed, Elizabeth Cecile

AU - Pelz, Corey J.

AU - Klein, John P.

AU - Sobocinski, Kathleen A.

AU - Kennedy, M. John

AU - Freytes, Cesar O.

AU - McCarthy, Philip L.

AU - Herzig, Roger H.

AU - Stadtmauer, Edward A.

AU - Lazarus, Hillard M.

AU - Pecora, Andrew L.

AU - Bitran, Jacob D.

AU - Wolff, Steven N.

AU - Gale, Robert Peter

AU - Armitage, James Olen

AU - Vaughan, William P.

AU - Spitzer, Gary

AU - Horowitz, Mary M.

PY - 1999/10/13

Y1 - 1999/10/13

N2 - Context: Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about the benefits of and appropriate patients for this therapy. Objective: To determine factors associated with disease progression or death after autotransplantation in women with metastatic breast cancer. Design: Analysis of data collected retrospectively (January 1989 to 1992) and prospectively (1992 through January 1995) for the Autologous Blood and Marrow Transplant Registry. Setting: Sixty-three hospitals in North America, Brazil, and Russia. Participants: A total of 1188 consecutive women aged 18 to 70 years receiving autotransplants for metastatic or locally recurrent breast cancer, with a median follow-up of 291/2 months. Main Outcome Measure: Time to treatment failure (disease progression, disease recurrence, or death) after autotransplantation. Results: Factors associated with significantly (P<.05) increased risk of treatment failure in a Cox multivariate analysis included age older than 45 years (relative hazard, 1.17; 95% confidence interval [Cl] 1.02-1.33). Karnofsky performance score less than 90% (1.27; 95% Cl, 1.07-1.51), absence of hormone receptors (1.31; 95% Cl, 1.151.51), prior use of adjuvant chemotherapy (1.31; 95% Cl, 1.10-1.56), initial disease-free survival interval after adjuvant treatment of no more than 18 months (1.99; 95% Cl, 1.62-2.43), metastases in the liver (1.47; 95% Cl, 1.20-1.80) or central nervous system (1.56; 95% Cl, 0.99-2.46 [approaches significance]) vs soft tissue, bone, or lung, 3 or more sites of metastatic disease (1.32; 95% Cl, 1.13-1.54), and incomplete response vs complete response to standard-dose chemotherapy (1.65; 95% Cl, 1.361.99). Receiving tamoxifen posttransplantation was associated with a reduced risk of treatment failure in women with hormone receptor-positive tumors (relative hazard, 0.60; 95% Cl, 0.47-0.87). Women with no risk factors (n = 38) had a 3-year probability of progression-free survival of 43% (95% Cl, 27%-61%) vs 4% (95% Cl, 2%8%) for women with more than 3 risk factors (n = 343). Conclusion: These data indicate that some women are unlikely to benefit from autotransplantation and should receive this treatment only after being provided with prognostic information and in the context of clinical trials attempting to improve outcome.

AB - Context: Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about the benefits of and appropriate patients for this therapy. Objective: To determine factors associated with disease progression or death after autotransplantation in women with metastatic breast cancer. Design: Analysis of data collected retrospectively (January 1989 to 1992) and prospectively (1992 through January 1995) for the Autologous Blood and Marrow Transplant Registry. Setting: Sixty-three hospitals in North America, Brazil, and Russia. Participants: A total of 1188 consecutive women aged 18 to 70 years receiving autotransplants for metastatic or locally recurrent breast cancer, with a median follow-up of 291/2 months. Main Outcome Measure: Time to treatment failure (disease progression, disease recurrence, or death) after autotransplantation. Results: Factors associated with significantly (P<.05) increased risk of treatment failure in a Cox multivariate analysis included age older than 45 years (relative hazard, 1.17; 95% confidence interval [Cl] 1.02-1.33). Karnofsky performance score less than 90% (1.27; 95% Cl, 1.07-1.51), absence of hormone receptors (1.31; 95% Cl, 1.151.51), prior use of adjuvant chemotherapy (1.31; 95% Cl, 1.10-1.56), initial disease-free survival interval after adjuvant treatment of no more than 18 months (1.99; 95% Cl, 1.62-2.43), metastases in the liver (1.47; 95% Cl, 1.20-1.80) or central nervous system (1.56; 95% Cl, 0.99-2.46 [approaches significance]) vs soft tissue, bone, or lung, 3 or more sites of metastatic disease (1.32; 95% Cl, 1.13-1.54), and incomplete response vs complete response to standard-dose chemotherapy (1.65; 95% Cl, 1.361.99). Receiving tamoxifen posttransplantation was associated with a reduced risk of treatment failure in women with hormone receptor-positive tumors (relative hazard, 0.60; 95% Cl, 0.47-0.87). Women with no risk factors (n = 38) had a 3-year probability of progression-free survival of 43% (95% Cl, 27%-61%) vs 4% (95% Cl, 2%8%) for women with more than 3 risk factors (n = 343). Conclusion: These data indicate that some women are unlikely to benefit from autotransplantation and should receive this treatment only after being provided with prognostic information and in the context of clinical trials attempting to improve outcome.

UR - http://www.scopus.com/inward/record.url?scp=0033552263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033552263&partnerID=8YFLogxK

U2 - 10.1001/jama.282.14.1335

DO - 10.1001/jama.282.14.1335

M3 - Article

VL - 282

SP - 1335

EP - 1343

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -